Flash FinanceUS
Market closed S&P 5007,549.94+2.35% Nasdaq25,253.14+2.74% Dow 3052,389.75+2.15% Russell 20002,840.81+3.15% Nasdaq-10027,907.62+3.40% MidCap 4003,715.23+3.13% SmallCap 6001,722.37+2.89% VIX19.92-22.31% 10Y Yield4.86+0.10% Close of Nov 09, 2026
AI brief of an SEC Form 8-K · Pluri Inc. (PLUR)

Pluri signs ZEO license deal and agrees to sell $1.0 million in stock to two investors

Neutral Impact 4 of 5 product/contract Written later

Pluri Inc. entered into a partnership agreement with ZEO ScientifiX on October 26, 2026, under which ZEO would receive an exclusive US license to manufacture and commercialize Pluri's regenerative medicine products, with Pluri receiving equity in ZEO at closing. On October 27, 2026, Pluri agreed to sell 909,092 common shares and warrants to two investors for $1.0 million in total, with closing expected on or before October 30, 2026. The stock sale adds shares outstanding, and the ZEO transaction depends on closing conditions, including agreement on an operating plan.

Key points

  • October 26, 2026: ZEO partnership grants ZEO an exclusive US license to manufacture and commercialize Pluri's regenerative medicine products, excluding certain aesthetics, skin care, cosmetic, or veterinary uses, which ZEO may only commerci
  • At closing, Pluri is to receive 41% of ZEO's issued and outstanding shares plus 50 Series D Preferred shares carrying 51% of ZEO's votes
  • October 27, 2026: two Securities Purchase Agreements for 909,092 common shares at $1.10 per share, with warrants for an equal number of shares at $1.30 per share; closing expected on or before October 30, 2026

The filing

CompanyPluri Inc. (PLUR)
Form8-K, current report
Filed with the SECOct 30, 2026, 8:30 AM ET
Accession number0001213900-26-114079

Items reported: 1.01 Material Definitive Agreement3.02 Unregistered Equity Sale8.01 Other Events

Read the filing on SEC.gov ↗

Written by AI on Nov 9, 2026, 8:36 AM ET, from this filing only. Written later: this filing was briefed after the fact, when past filings were added to the site, so the brief may be read with hindsight; the filing itself is the record of what was known on October 30, 2026.

Briefs are written by AI from the filing text and can contain mistakes — open the filing before acting on anything. Impact (1-5) and tone are the AI's reading of the filing for shareholders, not a price forecast. Not investment advice.